Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of VES001 in healthy participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia
• Frontotemporal Dementia

Drugs mentioned

• VES001

Snippet

Sponsor: Vesper Biotechnologies ApS | Conditions: Dementia, Frontotemporal | Phase 1 | Status: COMPLETED